
|Videos|November 21, 2017
Dr. Inman on Immunotherapy Combinations in Bladder Cancer
Author(s)Brant Inman, MD
Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.
Advertisement
Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.
Patients with metastatic bladder cancer whose tumors did not respond to chemotherapy should consider using one of the checkpoint inhibitors, states Inman.
The other situation is for patients who are ineligible for cisplatin. According to Inman, if a patient cannot receive cisplatin, the best choice is to consider a checkpoint inhibitor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































